| Trial ID: | L4727 |
| Source ID: | NCT00551590
|
| Associated Drug: |
Placebo Tablet
|
| Title: |
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Placebo tablet|DRUG: Sitagliptin tablet|DRUG: Saline infusion|DRUG: Exendin(9-39) infusion
|
| Outcome Measures: |
Primary: To asses the effect of sitagliptin compared to placebo and to coadministration of sitagliptin and the GLP-1 receptor antagonist exendin(9-39)NH2 on the incretin effect after an oral glucose challenge., during 240 minutes after ingestion of an OGTT | Secondary: Plasma glucagon, plasma GIP, plasma GLP-1, Insulin, C-peptide, plasma glucose profiles. 13CO2 exhalation kinetics assessing gastric emptying, during 240 minutes after ingestion of an OGTT
|
| Sponsor/Collaborators: |
Sponsor: Ludwig-Maximilians - University of Munich | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2007-12
|
| Completion Date: |
2011-09
|
| Results First Posted: |
|
| Last Update Posted: |
2011-10-04
|
| Locations: |
Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich, 81377, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00551590
|
